

## Cancer Association of South Africa (CANSA)




### Fact Sheet on Acute Myelomonocytic Leukaemia

#### Introduction

Leukaemia is a cancer of the white blood cells. All blood cells are produced in the bone marrow, the spongy substance at the core of some of the bones in the body.

[Picture Credit: Acute Myelomonocytic Leukaemia  
Bone Marrow Aspirate]



#### Acute Myelomonocytic Leukaemia (AMML)

Acute Myelomonocytic Leukemia (AMML) is a form of Acute Myeloid Leukaemia that involves a proliferation of both neutrophil and monocyte precursors with 20% or more myeloblasts in the bone marrow.

**Parsi, M., Go, M.S. & Ahmed, A. 2020.**

“Leukemia cutis characteristically demonstrates the infiltration of the skin by neoplastic leukocytes. While the extramedullary collection of leukemic cells is generally regarded as myeloid sarcoma (previously chloroma/granulocytic sarcoma), leukemia cutis is a generic term to describe specific cutaneous involvement. Although any subtype of leukemia can involve the skin, the most common types seen in clinical practice are chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) with monocytic or myelomonocytic morphology. Involvement by chronic myeloid leukemia (CML) is extremely rare and may be indicative of the blast phase. Patients usually have a prior diagnosis of systemic leukemia or myelodysplasia. However, cutaneous lesions may present as the primary manifestation of systemic disease in rare cases. Cutaneous involvement is generally indicative of advanced disease and should stipulate the investigation of other body sites for extramedullary involvement.”

**Kim, H.B., Park, S.G., Hong, R., Kang, S.H. & Na, Y.S. 2020.**

**Background:** Pembrolizumab is a highly selective IgG4 kappa isotype monoclonal antibody against the programmed cell death-1 (PD-1) molecule. In the treatment of non-small cell lung cancer (NSCLC), pembrolizumab has demonstrated significant efficacy, significant survival outcomes, long-lasting responses, and a good safety profile compared with cytotoxic chemotherapy.

---

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Dip Audiometry and Noise Measurement; Diagnostic Radiographer; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

January 2021

**Case summary:** A 79-year-old Korean male presented with a left side palpable neck mass. An ultrasound-guided core-needle biopsy of the largest neck mass was performed, and squamous cell carcinoma was confirmed based on the histological and immunohistochemical findings. He was diagnosed with squamous cell carcinoma of the lung with multiple lymph nodes and rib metastases (T1N3M1b, Stage IVA) using enhanced chest computed tomography and <sup>18</sup>F-fluorodeoxyglucose positron emission/computed tomography. After 4 cycles of gemcitabine and carboplatin, we clinically judged the disease as progressive. Owing to the high PD-1 expression demonstrated by the patient, pembrolizumab was initiated (200 mg every 3 wk). After 3 cycles of pembrolizumab, a complete response was achieved. At the 4<sup>th</sup> cycle of pembrolizumab, the white blood cell count was markedly elevated. Peripheral blood smear analysis and bone marrow biopsy were performed. The patient was diagnosed with acute myelomonocytic leukemia.

**Conclusion:** We present the first report of acute myelomonocytic leukemia during pembrolizumab treatment in an NSCLC patient; the mechanism remains unknown.

**Li, W., Cooley, L.D. & August, K. 2018.**

“Juvenile myelomonocytic leukemia (JMML) is a rare aggressive childhood leukemia characterized by an excess proliferation of cells of granulocytic and monocytic lineages. The WHO classifies JMML with the myelodysplastic/myeloproliferative neoplasms. Myelodysplasia in JMML is usually minimal to mild. Auer rods have never been reported in JMML. We present a 2-year-old boy with splenomegaly, leukocytosis, thrombocytopenia, anemia, and excess myeloblasts with easily seen Auer rods, and marked dysgranulopoiesis and dyserythropoiesis. Conventional cytogenetic analysis showed a sole abnormality of t(3;5)(q25;q35). Microarray analysis showed a terminal 21 Mb region of copy-neutral loss of heterozygosity on 19q. Disease-related somatic NRAS mutation was detected. This case represents an unusual JMML with Auer rods and marked myelodysplasia. These unusual histopathologic features may be related to the t(3;5)(q25;q35). A t(3;5) with variable breakpoints has been reported in a small proportion of acute myeloid leukemias and myelodysplastic syndromes. To our knowledge, this is the first JMML case reported with this translocation.”

**Xie, W., Hu, S., Xu, J., Chen, Z., Medeiros, L.J. & Tang, G. 2019.**

“t(8;16)(p11.2;p13.3)/KAT6A-CREBBP is a rare recurrent cytogenetic abnormality associated with acute myeloid leukemia (AML). We report 15 cases with t(8;16)(p11.2;p13.3). All patients were adult and had AML: 13 women and 2 men, with a median age of 50 years. Ten patients had a history of malignancy and received cytotoxic therapies before therapy-related AML (t-AML), and five patients had de novo AML. All cases of AML showed monoblastic (n = 12) or myelomonocytic (n = 3) differentiation. Hemophagocytosis was observed in seven patients. All patients had t(8;16) in the stemline: seven had t(8;16) as the sole abnormality, two had one additional abnormality, and six had a complex karyotype. KAT6A/CREBBP rearrangement was confirmed by fluorescence in situ hybridization in 13 patients who had material available for analysis. All patients received induction chemotherapy, and 11 achieved complete remission after first induction. At the time of last follow-up, nine patients (eight t-AML and one de novo AML) died and six were alive, with a median overall survival of 18.2 months. The patients with de novo AML and/or patients with non-complex karyotype showed an "undefined" overall survival. We conclude that t(8;16)(p11.2;p13.3) commonly exhibits monoblastic or myelomonocytic differentiation and commonly arises in patients with a history of cancer treated with cytotoxic therapies. Patients with de novo AML with t(8;16) or t-AML with t(8;16) without adverse prognostic factors (e.g., complex karyotype) have a good outcome.”

### Incidence of Acute Myelomonocytic Leukaemia (AMML)

In providing the incidence figures of Leukaemia in South Africa, the outdated National Cancer Registry (2017) does not make provision for the reporting of the different types of Leukaemia – it also does not differentiate between acute and chronic Leukaemia - neither does it provide for different statistics for cases of adult and childhood Leukaemia - except in the 'Frequency of Histologically Diagnosed Cancer in South Africa' Section of the Registry .

According to the National Cancer Registry (2017) the following number of Leukaemia cases was histologically diagnosed in South Africa during 2017:

Group - Males	Actual	Estimated	Percentage of All Cancers
2017	No of Cases	Lifetime Risk	
All males	338	1:634	0,85%
Asian males	7	1:1 000	0,72%
Black males	151	1:1 357	1,12%
Coloured males	29	1:862	0,58%
White males	151	1:209	0,72%

Group - Females	Actual	Estimated	Percentage of All Cancers
2017	No of Cases	Lifetime Risk	
All females	230	1:1 289	0,55%
Asian females	8	1:1 010	0,62%
Black females	106	1:2 410	0,56%
Coloured females	25	1:1 074	0,53%
White females	91	1:455	0,52%

The frequency of histologically diagnosed cases of Leukaemia in South Africa for 2017 was as follows (National Cancer Registry, 2017):

Group - Males	0 – 19	20 – 29	30 – 39	40 – 49	50 – 59	60 – 69	70 – 79	80+
2017	Years	Years	Years	Years	Years	Years	Years	Years
All males	82	21	29	33	54	61	42	16
Asian males	0	0	3	1	1	1	1	0
Black males	66	10	19	16	16	19	4	1
Coloured males	7	2	1	4	6	3	5	1
White males	9	9	6	12	31	38	3	14

Group - Females	0 – 19	20 – 29	30 – 39	40 – 49	50 – 59	60 – 69	70 – 79	80+
2017	Years	Years	Years	Years	Years	Years	Years	Years
All females	40	17	20	28	31	39	37	18
Asian females	1	1	0	0	2	3	1	0
Black females	32	10	17	12	15	14	2	4
Coloured females	1	3	0	5	4	6	5	1
White females	6	3	3	11	10	16	29	13

N.B. In the event that the totals in any of the above tables do not tally, this may be the result of uncertainties as to the age, race or sex of the individual. The totals for 'all males' and 'all females', however, always reflect the correct totals.

## Signs and Symptoms of Acute Myelomonocytic Leukaemia

Signs and symptoms include:

- Looking very pale
- Fever
- Regular infections
- Bone pain
- Lethargy and fatigue
- Shortness of breath
- Easy bruising
- Having fever and sweating
- Unusual bleeding, such as frequent nosebleeds and bleeding from the gums

## Diagnosis of Acute Myelomonocytic Leukaemia

The following tests may be done to assist in making a diagnosis of Acute Myelomonocytic Leukaemia:

Taking of complete medical history

- Physical examination
- Bone Marrow Biopsy
- Bone Marrow Aspiration
- Peripheral Blood Smear
- Complete Blood Count (CBC)
- Blood chemistry
- Blood coagulation test
- Flow cytometry
- Cerebrospinal fluid examination
- Immunohistochemistry
- Cytogenetics
- Fluorescent *in situ* hybridisation (FISH)
- Polymerase Chain Reaction (PCR)

## Risk Factors for Acute Myelomonocytic Leukaemia (AMML)

Factors that may increase one's risk for acute myelogenous leukaemia include:

- Increasing age
- Being male
- Previous cancer treatment
- Exposure to radiation
- Exposure to certain chemicals, such as benzene
- Smoking
- People who have had another blood disorder, such as myelodysplasia, polycythaemia vera or thrombocythaemia
- Certain genetic disorders, such as Down syndrome
- Many people with AMML have no known risk factors

## Treatment of Most Cases of Acute Myelomonocytic Leukaemia (AMML)

Treatment of most cases of acute myeloid leukaemia (AMML) is usually divided into 2 chemotherapy phases and may include:

- Remission induction (often just called *induction*) – getting rid of as many leukaemia cells as possible
- Consolidation (post-remission therapy) - treatment is given to try to destroy any remaining leukaemia cells and help prevent a relapse

Treatment usually needs to start as quickly as possible after the diagnosis because AML can progress very quickly.

One or more of the following four types of standard treatments may be used:

- Chemotherapy
- Radiation therapy
- Stem cell transplant
- Other drug therapy

New types of treatment being tested in clinical trials:

- Targeted therapy

Patients may consider taking part in a clinical trial.

Follow-up tests may be needed. Patients should consult their treating physician in this regard.

**Helbig, G., Chromik, K., Woźniczka, K., Kopińska, A.J., Boral, K., Dworaczek, M., Kocłęga, A., Armatys, A., Panz-Klapuch, M. & Markiewicz, M. 2019.**

“The administration of azacitidine (AZA) was found to be more effective than conventional care regimen (CCR) in patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) with lower blast count. We designed a study to determine efficacy and safety of AZA therapy in "real life" patients with MDS, CMML and AML. The study included 83 patients (65% male) with a median age at diagnosis of 68 years. 43 patients were diagnosed with higher-risk MDS, 30 had AML and 10-CMML. Median AZA dose was comparable between treated groups. AZA dose reduction was required for 44% of MDS, 17% of AML and 25% of CMML patients. Complete remission (CR) was achieved in 14% of MDS, 7% of AML and 10% of CMML patients. Overall response rate was following: 27% for MDS, 20% for AML and 20% for CMML. Estimated OS at 12 months was 75% for MDS, 60% for AML and 75% for CMML. Median follow-up for MDS/AML/CMML from AZA initiation to last follow-up was 9.0, 9.4 and 9.4 months, respectively. The most common toxicity of AZA therapy was myelosuppression and infections. AZA treatment was effective in a limited number of patients with acceptable safety profile.”

## About Clinical Trials

Clinical trials are research studies that involve people. They are conducted under controlled conditions. Only about 10% of all drugs started in human clinical trials become an approved drug.

Clinical trials include:

- Trials to test effectiveness of new treatments

---

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Dip Audiometry and Noise Measurement; Diagnostic Radiographer; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

January 2021

- Trials to test new ways of using current treatments
- Tests new interventions that may lower the risk of developing certain types of cancers
- Tests to find new ways of screening for cancer

The South African National Clinical Trials Register provides the public with updated information on clinical trials on human participants being conducted in South Africa. The Register provides information on the purpose of the clinical trial; who can participate, where the trial is located, and contact details.

For additional information, please visit: [www.sanctr.gov.za/](http://www.sanctr.gov.za/)

### Medical Disclaimer

This Fact Sheet is intended to provide general information only and, as such, should not be considered as a substitute for advice, medically or otherwise, covering any specific situation. Users should seek appropriate advice before taking or refraining from taking any action in reliance on any information contained in this Fact Sheet. So far as permissible by law, the Cancer Association of South Africa (CANSA) does not accept any liability to any person (or his/her dependants/estate/heirs) relating to the use of any information contained in this Fact Sheet.

Whilst CANSA has taken every precaution in compiling this Fact Sheet, neither it, nor any contributor(s) to this Fact Sheet can be held responsible for any action (or the lack thereof) taken by any person or organisation wherever they shall be based, as a result, direct or otherwise, of information contained in, or accessed through, this Fact Sheet.



### Sources and References Consulted and/or Utilised

#### Acute Myelomonocytic Leukaemia – Bone Marrow Aspirate

<https://basicmedicalkey.com/acute-myeloid-leukemia/>

#### American Cancer Society

<https://www.cancer.org/cancer/acute-myeloid-leukemia/treating/typical-treatment-of-aml.html>

**Helbig, G., Chromik, K., Woźniczka, K., Kopyńska, A.J., Boral, K., Dworaczek, M., Kocłega, A., Armatys, A., Panz-Klapuch, M. & Markiewicz, M.** 2019. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. *Pathol Oncol Res.* 2019 Jan 6. doi: 10.1007/s12253-018-00574-0. [Epub ahead of print]

**Hu, Z., Hu, S., Ji, C., Tang, Z., Thakral, B., Loghavi, S., Medeiros, L.J. & Wang, W.** 2017. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: an early event associated with a poor prognosis. *Leuk Res.* 2017 Dec 23;65:25-28/ doi: 10.1016/j.leukres. 2017. 12.2004. [Epub ahead of print].

**Kim, H.B., Park, S.G., Hong, R., Kang, S.H. & Na, Y.S.** 2020. Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: a case report. *World J Clin Cases.* 2020 Jul 6;8(13):2833-2840.

**Li, W., Cooley, L.D. & August, K.** 2018. Juvenile myelomonocytic leukemia with t(3:5)(q25:q35), Auer rods and marked myelodysplasia. *Pathol Res Pract.* 2018 Jun;214(6):919-923. doi: 10.1016/j.prp.2017.11.024. Epub 2017 Dec 5.

---

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Dip Audiometry and Noise Measurement; Diagnostic Radiographer; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

January 2021

**MacMillan Cancer Support**

[http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Childrencancers/Typesofchildrencancers/Acutemyeloidleukaemia.aspx#DynamicJumpMenuManager\\_6\\_Anchor\\_1](http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Childrencancers/Typesofchildrencancers/Acutemyeloidleukaemia.aspx#DynamicJumpMenuManager_6_Anchor_1)

**Mayo Clinic**

<https://www.mayoclinic.org/diseases-conditions/acute-myelogenous-leukemia/basics/symptoms/con-20043431>  
<https://www.mayoclinic.org/diseases-conditions/acute-myelogenous-leukemia/basics/risk-factors/con-20043431>

**National Cancer Institute**

<http://www.cancer.gov/cancertopics/pdq/treatment/childAML/Patient/page1#Keypoint4>  
<http://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials>

**Nomdedeu, M., Pereira, A., Calvo, X., Colomer, J., Sole, F., Arias, A., Gomez, C., Luño, E., Cervera, J., Arnan, M., Pomares, H., Ramos, F., Oiartzabal, I., Espinet, B., Pedro, C., Arrizabalaga, B., Blanco, M.L., Tormo, M., Hernandez-Rivas, J.M., Díez-Campelo, M., Ortega, M., Valcárcel, D., Cedena, M.T., Collado, R., Grau, J., Granada I., Sanz, G., Campo, E., Esteve, J., Costa, D. & Spanish MDS Group.** 2017. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukaemia: a report from the Spanish MDS Group. *Leuk Res.* 2017 Dec; 63:85-89. Doi: 10.1016/j.leukres. 2017. 10.10011. Epub 2017 Oct 28. PMID: 29121539.

**Parsi, M., Go, M.S. & Ahmed, A.** 2020. Leukemia cutis. *In:* StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. 2020 Aug 8.

**Pathology Outlines**

<http://www.pathologyoutlines.com/topic/leukemiaM4.html>

**Science Direct**

<http://www.sciencedirect.com/topics/medicine-and-dentistry/acute-myelomonocytic-leukemia>

**Wikipedia**

[https://en.wikipedia.org/wiki/Acute\\_myelomonocytic\\_leukemia](https://en.wikipedia.org/wiki/Acute_myelomonocytic_leukemia)

**Xie, W., Hu, S., Xu, J., Chen, Z., Medeiros, L.J. & Tang, G.** 2019. Acute myeloid leukaemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults. *Ann Hematol.* 2019 Feb 13. doi: 10.1007/s00277-019-03637-7. [Epub ahead of print]